AVXL

Anavex Life Sciences

1.13

USD

-0.09

-7.38%

Nov 10, 15:59 UTC -5

Closed

After-Market

1.12

-0.01

-0.80%

Anavex Life Sciences (AVXL) Earnings

AVXL Earnings Reports

Positive Surprise Ratio

AVXL beat 27 of 39 last estimates.

69%

Next Report

Date of Next Report

Nov 23, 2026

Estimate for Q4 26 (Revenue/ EPS)

-$0.11

Implied change from Q3 26 (Revenue/ EPS)

+37.50%

Implied change from Q4 25 (Revenue/ EPS)

Anavex Life Sciences earnings per share and revenue

On Aug 25, 2026, AVXL reported earnings of -0.08 USD per share (EPS) for Q3 26, beating the estimate of -0.08 USD, resulting in a 1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +14.47% price change (close before vs. close after earnings).

Looking ahead to Q4 26, 5 analysts forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an increase of 37.50% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Anavex Life Sciences's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Anavex Life Sciences reported EPS of -$0.08, beating estimates by 1.96%, and revenue of $0.00, 0% as expectations.

How did the market react to Anavex Life Sciences's Q3 2026 earnings?

The stock price moved up 14.47%, changed from $3.11 before the earnings release to $3.56 the day after.

When is Anavex Life Sciences expected to report next?

The next earning report is scheduled for Nov 23, 2026.

What are the forecasts for Anavex Life Sciences's next earnings report?

Based on 5 analysts, Anavex Life Sciences is expected to report EPS of -$0.11 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.